Clinical Trials Logo

Clinical Trial Summary

BACKGROUND: Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder. The Ca/P ratio is an accurate tool to differentiate patients with PHPT (>3.5 if Ca and P are expressed in mg/dl) from healthy subjects. The reliability of this index is based on the fact that serum Ca and P are inversely related together. However, other disorders of the Ca-P metabolism, such as hypophosphoremia (HypoP) not related to PHPT, might also impair the Ca/P ratio.

OBJECTIVE: To validate the accuracy of Ca/P ratio in the diagnosis of Ca-P metabolism disorders, including also patients with documented HypoP not related to PHPT.

METHODS: A single-center, retrospective, case-control study will be carried out.

Biochemical measurements will include parathormone (PTH), vitamin D, serum Ca and P, serum albumin and creatinine.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03603444
Study type Observational
Source Azienda Ospedaliero-Universitaria di Modena
Contact
Status Completed
Phase
Start date January 1, 2011
Completion date January 1, 2018

See also
  Status Clinical Trial Phase
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Recruiting NCT05141838 - Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa Phase 4
Active, not recruiting NCT04019379 - Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease N/A